Clinical Trial Update: A Long Term Safety Study of BCX7353 in Hereditary Angioedema [Phase 2, Phase 3]

View source ↗

Summary

Long-term safety study of BCX7353 in hereditary angioedema has completed phases 2 and 3 with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• BCX7353

Snippet

Sponsor: BioCryst Pharmaceuticals | Conditions: Hereditary Angioedema, HAE | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2023-06-18